Reported Sunday, Celldex Presents Phase 1 CDX-622 Data At EAACI 2026 Showing Bispecific Antibody Targeting Soluble SCF And TSLP Achieves Profound Mast Cell Depletion With Favorable Safety Profile

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.

CLDX

0.00
  • CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseases
  • CDX-622 targets the soluble form of stem cell factor (SCF), depleting mast cells without measurably impacting other KIT functions
  • Rapid, profound, dose-dependent, and durable reductions in serum tryptase observed
  • Well-tolerated at all dose levels
  • First company to demonstrate that neutralizing soluble SCF can selectively inhibit KIT signaling in mast cells
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.